ArticleJournal of gastroenterology2023

Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.

Kosuke Morimoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.